A

Arvinas

D
ARVN
USD
0.63
(2.522%)
Market Closed
18,694.00
Volume
-4.1
EPS
-
Div Yield
-4.832075
P/E
1,758,076,842.21
Market Cap
Today
2.5220%
1 Week
4.488%
1 Month
0.589%
6 Months
-39.784%
12 Months
4.488%
Year To Date
-37.840%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
MRNA
MRNA
-1.79
(-2.5637%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
E
EDIT
0.05
(1.292%)
USD
S
SGMO
0.0617
(7.3584%)
USD
C
CRIS
-0.15
(-2.5084%)
USD
ABBV
ABBV
0.73
(0.3784%)
USD
REGN
REGN
11.33
(0.9948%)
USD
S
SAGE
0.32
(4.2161%)
USD
B
BLUE
-0.0046
(-0.9287%)
USD
GILD
GILD
0.015
(0.0179%)
USD

Title:
Arvinas

Sector:
Healthcare
Industry:
Biotechnology
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Do you need help or have a question?
Contact Us